Michael F. Cannon is director of health policy studies at the Cato Institute.
It's Time for Over-the-Counter Ozempic
There's an easy way to lower the cost of next-generation weight-loss drugs.
Michael F. Cannon
Latest from Michael F. Cannon
The Case for Letting Medicare Bureaucrats Haggle With Drug Makers
Medicare's new price-setting process for drug purchases is better than its current one if the result is lower government spending.
Department of Veterans Affairs
The V.A.'s Biggest Problem Isn't Who's In Charge—It's Centralized Government Control
With Trump's nominee Ronny Jackson out, here's how to fix veterans health care.
